Pharma Mar (XMAD:PHM) Cyclically Adjusted Revenue per Share: €12.01 (As of Mar. 2026)


XMAD:PHM Pharma Mar SA XMAD:PHM
83 GF Score
Price €78.80
GF Value €82.07
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Pharma Mar Cyclically Adjusted Revenue per Share?

Pharma Mar XMAD:PHM -4.08% 83 Cyclically Adjusted Revenue per Share is €12.01 as of Mar. 2026. GuruFocus rates XMAD:PHM with a GF Score™ of 83/100 and a GF Value™ of €82.07 (Fairly Valued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Pharma Mar's adjusted revenue per share for the three months ended in Mar. 2026 was €2.479. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €12.01 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Pharma Mar's average Cyclically Adjusted Revenue Growth Rate was 5.20% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 3.60% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 4.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Pharma Mar was 6.30% per year. The lowest was -0.50% per year. And the median was 3.60% per year.

As of today (2026-07-12), Pharma Mar's current stock price is €78.80. Pharma Mar's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €12.01. Pharma Mar's Cyclically Adjusted PS Ratio of today is 6.56.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Pharma Mar was 14.45. The lowest was 1.21. And the median was 5.07.


Pharma Mar  (XMAD:PHM) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Pharma Mar's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=78.80/12.01
=6.56

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Pharma Mar was 14.45. The lowest was 1.21. And the median was 5.07.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Pharma Mar Cyclically Adjusted Revenue per Share Related Terms


Pharma Mar Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Pharma Mar's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharma Mar Cyclically Adjusted Revenue per Share Chart

Pharma Mar Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.17 10.73 11.04 11.44 11.92

Pharma Mar Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.42 11.56 11.37 11.92 12.01

XMAD:PHM vs VRTX, REGN, ALNY: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Pharma Mar's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharma Mar Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharma Mar's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Pharma Mar's Cyclically Adjusted PS Ratio falls into.


XMAD:PHM
83GF Score
Pharma Mar SA XMAD:PHM
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharma Mar Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Pharma Mar's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=2.479/129.8600*129.8600
=2.479

Current CPI (Mar. 2026) = 129.8600.

Pharma Mar Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 2.709 100.333 3.506
201609 2.575 99.737 3.353
201612 2.244 101.842 2.861
201703 2.469 100.896 3.178
201706 2.794 101.848 3.562
201709 1.464 101.524 1.873
201712 1.897 102.975 2.392
201803 1.510 102.122 1.920
201806 2.093 104.165 2.609
201809 1.214 103.818 1.519
201812 1.084 104.193 1.351
201903 1.053 103.488 1.321
201906 1.191 104.612 1.478
201909 1.142 103.905 1.427
201912 1.262 105.015 1.561
202003 5.380 103.469 6.752
202006 3.791 104.254 4.722
202009 2.922 103.521 3.665
202012 2.639 104.456 3.281
202103 2.824 104.857 3.497
202106 2.613 107.102 3.168
202109 2.312 107.669 2.789
202112 4.969 111.298 5.798
202203 2.953 115.153 3.330
202206 2.667 118.044 2.934
202209 2.437 117.221 2.700
202212 2.806 117.650 3.097
202303 1.891 118.948 2.064
202306 2.571 120.278 2.776
202309 2.105 121.343 2.253
202312 2.296 121.300 2.458
202403 2.168 122.762 2.293
202406 2.444 124.409 2.551
202409 2.628 123.121 2.772
202412 5.349 124.753 5.568
202503 2.220 125.531 2.297
202506 3.235 127.251 3.301
202509 2.077 126.840 2.126
202512 7.392 128.400 7.476
202603 2.479 129.860 2.479

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €12.01 mean?
Pharma Mar (XMAD:PHM) has a Cyclically Adjusted Revenue per Share of €12.01 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Pharma Mar and its competitors.
Is Pharma Mar's Cyclically Adjusted Revenue per Share too high?
Pharma Mar's current Cyclically Adjusted Revenue per Share is €12.01. Overall, Pharma Mar has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pharma Mar's Cyclically Adjusted Revenue per Share compare to VRTX and REGN?
Pharma Mar's Cyclically Adjusted Revenue per Share of €12.01 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Pharma Mar and its competitors. Pharma Mar's current Cyclically Adjusted Revenue per Share is €12.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma Mar stock overvalued right now?
Based on GuruFocus' analysis, Pharma Mar (XMAD:PHM) is currently considered Fairly Valued. The stock's GF Value™ is €82.07, compared to a current price of €78.80 — trading 4% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €12.01. Pharma Mar's overall GF Score™ is 83/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Pharma Mar (XMAD:PHM), the current Cyclically Adjusted Revenue per Share is €12.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pharma Mar (XMAD:PHM) Overvalued in 2026?

Based on GuruFocus' analysis, Pharma Mar stock appears to be undervalued. The current stock price of €78.80 is trading 4% below its estimated GF Value™ of €82.07. GuruFocus considers Pharma Mar to be Fairly Valued.

Key valuation signals for XMAD:PHM:

  • Cyclically Adjusted Revenue per Share: €12.01
  • GF Value™: €82.07 vs. price of €78.80 (4% below fair value)
  • GF Score™: 83/100 with 3 warning signs

No single metric tells the full story. See the XMAD:PHM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pharma Mar Business Description

Address Avenida de los Reyes, 1, Poligono Industrial La Mina-norte, Colmenar Viejo, Madrid, ESP, 28770
Pharma Mar SA is engaged in the research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It also produces and markets insecticides and air fresheners for household use, household products, wood treatment and decoration products, paints, and similar products. Its operating business segments are Oncology and RNAi. The company obtains its revenues from two main areas: biopharmaceuticals and consumer chemicals, but the biopharmaceuticals is the main line of business.
83GF Score

Get the complete analysis for XMAD:PHM

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€78.80
Price
€82.07
GF Value